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Abstract
Giant cell arteritis (GCA) is a granulomatous vasculitis affecting large- and 
medium-sized arteries in the elderly and potentially causes visual loss. In an elderly 
patient presenting with acute pain in the distribution of the external carotid artery 
(e.g., headache, scalp tenderness); polymyalgia rhematica; or acute/transient visual 
loss or diplopia; a possibility of GCA should be considered in one of the differential 
diagnosis. Urgent laboratory evaluation (e.g., ESR, CRP, platelet count), followed 
immediately by empiric high-dose corticosteroid therapy is warranted in patients 
suspected of having GCA. Although ultrasound techniques are sensitive for the 
diagnosis of GCA, TAB remains the best confirmatory test. Patients with GCA 
often require long durations of steroid therapy and steroid-related complications 
are common. Multidisciplinary care and the use of steroid-sparing regimens are 
warranted in case of relapse.
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1. Introduction
Giant cell arteritis (GCA) is a granulomatous vasculitis affecting medium to 
large sized arteries, it most commonly involves the aorta, branches of the ophthal-
mic artery, and extracranial branches of the carotid arteries [1–5]. From a clinical 
perspective, GCA is a medical emergency because if undiagnosed and treated 
early, ischemic complications may cause permanent vision loss in up to 15–25% of 
cases [6]. Early diagnosis and initiation of treatment is essential to improve visual 
and systemic prognosis in patients with GCA [1, 7, 8]. The complications of GCA 
result from ischemic injury, systemic inflammation, and aneurysm formation and 
rupture. Early initiation of corticosteroids in patients with suspected GCA has been 
found to significantly reduce the risk of permanent visual loss in various stud-
ies [6–8]. In this review we provide a brief overview regarding the pathogenesis, 
clinical features, investigations and management of GCA from a Neurologist’s 
perspective.
2. Pathophysiology
GCA is immune-mediated inflammatory vasculitis affecting the medium 
and large-size arteries. The immunological cascade is triggered by an unknown 
antigen that begins with the dendritic cell processing the antigen and presenting 
it to T cells via the major histocompatibility complex II interaction with the T cell 
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receptors [1, 2, 6, 9]. In this inflammatory cascade, there is downstream activation 
and differentiation of T cells to TH1 and TH17 cells, which in turn express inter-
feron γ, a potent macrophage activator. This macrophage activation causes further 
release of chemokines including but not limited to IL-6 and tumor necrosis factor 
(TNF) alpha. A large number of inflammatory cells are recruited with production 
of reactive oxygen species (ROS) and matrix metalloproteinases (MMPs), which 
then primarily attack the internal elastic lamina of blood vessels. This mechanism 
damages the vessel wall leading to abnormal vascular remodeling and ultimately 
occlusion of the vessel lumen [10, 11].
2.1 Risk factors
GCA generally affects elderly population, with the average age of presentation 
being 74–76 years, and peak incidence at 80 years [3, 5, 9]. While GCA can occur in 
both men and women, it is more common in women. Women have an increased risk 
ranging from 2.3 to 2.6 times compared to men [1, 3, 9]. Additionally, It has been 
found to be affecting Caucasian ethnicity more especially those of Scandinavian, 
Nordic, or Northern-European ancestry [1, 3, 9]. Other important independent risk 
factors are smoking, early menopause and low body mass index [9, 12].
2.2 Clinical symptoms and examination findings
The symptoms of GCA include both systemic and ocular. New-onset headache 
is the most common systemic symptom and the systemic symptoms often precede 
the ocular manifestations. Fifty percent of patients with GCA have systemic 
symptoms and these include myalgias, headaches, scalp and temporal artery 
tenderness, jaw and rarely arm claudication, and constitutional symptoms (e.g., 
fever, anorexia, and weight loss) [1, 5]. Polymyalgia rheumatica (PMR) is present 
in approximately 50% of patients with biopsy-proven GCA [5]. The characteristic 
symptoms of PMR include: persistent pain for at least 1 month with episodes of 
aching and morning stiffness that lasts at least 30 minutes in the neck, shoulder, or 
pelvic girdle and an elevated ESR of at least 40 mm/h [5].
The most severe ocular manifestation of GCA is visual loss, with 50% of patients 
complaining of ocular involvement ranging from eye pain to amaurosis fugax. 
19 Ocular involvement is more commonly seen in elderly patients compared to 
younger individuals, with no gender predilection [9, 13]. The ocular complaints 
include visual loss of varying severity, amaurosis fugax, diplopia, and eye pain 
[13]. Amaurosis fugax, precedes permanent vision loss in 44% of GCA patients [5]. 
Vision loss is usually mono-ocular to begin with and if left untreated, contralateral 
eye involvement commonly occurrs between 1 and 14 days after initial onset with 
the longest interval being 9 months [5, 13]. When treated early and adequately with 
corticosteroids, GCA-mediated blindness is preventable in majority of cases [9, 13].
In a case of suspected giant cell arteritis, the following clinical approach is 
recommended [4]:
• Palpation of the Temporal artery: Temporal artery may be tender, thickened 
and beaded. The pulse may be difficult to feel and patient may complain of 
scalp tenderness.
• The systemic examination should be directed at looking for evidence of large 
vessel vasculitis, that is looking for delayed or absent pulses in upper limbs, 
subclavian or carotid bruits, and blood pressure asymmetry in the limbs.
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• Detailed ophthalmological exam is warranted – look for transient or perma-
nent visual loss, visual field defect, relative afferent pupillary defect, anterior 
ischemic optic neuritis, central retinal artery occlusion.
2.3 Investigations
The following investigations are recommended in evaluation of suspected 
giant cell arteritis complete blood count, renal function tests, liver function tests, 
C-reactive Protein (CRP) and erythrocyte sedimentation rate (ESR) [1–5]. There 
is often evidence of an acute-phase response on blood tests. Other investigations 
recommended are Chest X-ray and urinalysis. Baseline (pre-treatment) markers of 
inflammation are also useful to assess response to treatment.
There are a number of investigations that can also be carried out to help confirm 
diagnosis, as outlined below.
• Temporal artery biopsy
The gold standard for diagnosis of giant cell arteritis is Temporal artery biopsy 
(TAB). 10–20% of GCA can be biopsy negative, however a negative result 
does not rule out the condition [1–5]. The findings on temporal artery biopsy 
in GCA is characterized by inflammatory infiltration of the arterial wall by 
lymphocytes, macrophages and giant cells in about 50% of cases [1–5].
• Temporal artery ultrasound (color-coded duplex sonography)
Color-coded duplex sonography can be utilized to examine the temporal, 
extracranial, occipital and subclavian arteries. An ultrasound study has a 
sensitivity of 85% and a specificity of more than 90% [1–4, 14]. The ‘halo sign’ 
where Inflammatory oedema of the vascular wall will be shown as hypoechoic 
wall thickening is characteristic.
• Positron emission tomography
PET uses radioactive metabolites to visualize metabolic processes. Spatial 
resolution is limited with PET, so visualization can only be determined in the 
aorta and larger vessels. The ability to visualize the temporal arteries is limited 
with PET. The European League Against Rheumatism (EULAR) do not advise 
PET to screen the cranial vessels, however by using newer PET scanners with 
improved spatial resolution the temporal arteries may be better visualized in 
the future [15, 16].
• High-resolution magnetic resonance imaging
For imaging of temporal arteries MRI is the imaging modality of choice recom-
mended by the EULAR [16]. Detailed imaging of the walls and lumen of the 
temporal artery is possible by doing a High-resolution MRI (fat suppression, 
T1 weighted) allows. A concurrent MR angiography allows imaging of large 
vessels such as aorta and sub-clavian artery.
3. Diagnosis of GCA
Diagnosis of GCA is based on clinical and laboratory tests and application of the 
revised ACR criteria (Table 1) [17]. It has been suggested that in the presence of 3 
points or more out of 11, with at least 1 point belonging to Domain 1, the diagnosis 





Initiation of prompt corticosteroid treatment is recommended [1–5]. In cases 
where there is a clinical suspicion of giant cell arteritis, corticosteroid treatment 
should be initiated immediately and not delayed awaiting results of blood tests or 
temporal artery biopsy.
In cases of complicated giant cell arteritis, that is when there is evolving visual 
loss or amaurosis fugax: Intravenous methylprednisolone in a dosage of 500 mg–1 g 
IV for three days followed by corticosteroid dose is advised.
A corticosteroid tapering regimen is suggested below [18]:
• Start with prednisolone 40–60 mg daily continue for at least three to four 
weeks until clinical symptoms and laboratory abnormalities begin to resolve
• Subsequently reduce the dose by 10 mg every two weeks to 20 mg daily, followed 
by further reduction of dose by 2.5 mg every two to four weeks to 10 mg daily
• Subsequently it is recommended to reduce the dose by 1 mg every one to two 
months, provided the condition does not relapse again.
Corticosteroids can generally be reduced when the clinical features of active 
disease are absent and when the laboratory markers for acute inflammation such as 
ESR, C-reactive protein are normalized.
4.2 Aspirin
The usage of Aspirin is controversial; albeit it remains in the recommendations 
[18], when not contraindicated. Aspirin has been found to be protective against 
SCORE
N/A Age at onset ≥50 years old







New onset localized headachec
Sudden onset of visual disturbancesc
Polymyalgia Rheumatica
Jaw Claudicationc





Unexplained fever and/or anemia 1 point
ESR ≥50 mm/houre 1p
Compatible pathologyf up to 2 points
aIn the presence of 3 points or more out of 11 with at least one point belonging to domain I along with all entry 
criteria, the diagnosis of Giant cell arteritis can be established.
bExclusion criteria are including: ENT and eye inflammation, kidney, skin and peripheral nervous system 
involvement, lung infiltration, lymphadenopathies, stiff neck and digital gangrene or ulceration.
cNo other aetiologies can better explain any one of the criteria.
d-Enlarged and/or pulseless temporal artery: 1 point/tender temporal artery: 1 point.
eIt must be ignored in the presence of PMR.
fVascular and/or perivascular fibrinoid necrosis along with leucocyte infiltration: 1 point and granuloma: 1 point.
Table 1. 
Revised ACR criteria (rACR) for diagnosis of GCAa [17].
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cerebrovascular and cardiovascular events in previous studies [19]. Apart from its 
antiplatelet effects and Aspirin also has disease-modifying effects through suppres-
sion of interferon (IFN) gamma [18, 19].
4.3 Management of relapse
All patients with suspected relapse should be referred to, or have their treatment 
discussed with, a specialist [1–5, 18, 19]. In case of relapse, a rise in inflammatory 
markers (ESR/CRP) is usually seen, however these markers can remain normal 
in some cases. In case of recurrence of headache, the patient should revert to the 
previous higher corticosteroid dosage. In case of jaw claudication, a prednisolone 
dosage of 60 mg daily is recommended. Ocular symptoms need prednisolone 60 mg 
daily orally or intravenous pulse methylprednisolone 1 g and immediate opthalmol-
ogy consultation.
4.4 Management of Recurrent relapse
Despite an initial good response to therapy, about 30–50% of patients will suffer 
a relapse, within the next two years [1–5, 18–20]. The use of secondary agents such 
as methotrexate (or others such as azathioprine in patients, who are intolerant to 
methotrexate) should be considered in patients with recurrent relapse or failure. 
Various clinical trials have shown that Methotrexate (7.5–15 mg once a week) 
reduces the relapse rate and overall duration of exposure to corticosteroids [20].
4.5 Tocilizumab
Tocilizumab is an interleukin-6 (IL-6)-receptor inhibitor. The Giant Cell 
Arteritis Actemra (GiACTA) trial demonstrated increased rates of sustained 
remission using a combination of tocilizumab plus corticosteroids compared with 
those treated with corticosteroids alone [21]. Furthermore, steroid-induced adverse 
effects were reduced with the usage of tocilizumab for treatment.
Tocilizumab is recommended by NICE as an option for treating GCA in adults, 
in case they have relapsing, or refractory disease and they have not already taken 
tocilizumab; it is stopped after one year of uninterrupted treatment at most [20].
Tocilizumab is a potent suppressor of IL-6, which is important producer of CRP. 
Therefore, patients on tocilizumab may not produce a biochemical inflammatory 
response in the setting of infection/inflammation. Caution should be taken while 
taking Tocilizumab, particularly in patients with a history of diverticulitis, as it 
carries a risk for gastrointestinal perforation [22].
5. Conclusion
In an elderly patient presenting with acute pain in the distribution of the exter-
nal carotid artery (e.g., headache, scalp tenderness); PMR; or acute/transient visual 
loss or diplopia; a possibility of GCA should be considered in one of the differential 
diagnosis. Urgent laboratory evaluation (e.g., ESR, CRP, platelet count), followed 
immediately by empiric high-dose corticosteroid therapy is warranted in patients 
suspected of having GCA. Although ultrasound techniques are sensitive for the 
diagnosis of GCA, TAB remains the best confirmatory test. Patients with GCA often 
require long durations of steroid therapy and steroid-related complications are 
common. Multidisciplinary care and the use of steroid-sparing regimens is war-
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